Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
about
Structural basis for activation of α-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptaseOptimal cytoplasmic transport in viral infectionsComparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switchingFunctional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variantsDifferent viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseApparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsComparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
P2860
Q27625384-BCD6D448-C19A-4DD0-9375-9DBE7871EAB2Q28472404-44DBEB29-0C95-4D5B-B9B6-9A7F1AC95357Q30394627-98FF9136-938A-489F-8B3C-A24E69329B26Q33809246-98CA30D0-4D82-495C-9C63-6D5FCEF7E34AQ33849423-47F43538-68CD-4914-AD7D-0198B41C0A73Q33873983-EDEB1438-7444-4F0F-AF27-28B2A5DB0EE5Q33906239-EC4CF974-1C4D-414B-8AC3-4F90E50AF862Q34058254-6189DBD0-14FD-480C-8653-2B30DD9FFBD3Q34465037-C81C9173-9467-468E-BDFC-3B2C0EC87053Q34573897-A299796E-FB36-48E3-A8A1-8AEDD9E46009Q35156768-5FAD58E0-6B0D-414A-AA6E-624C0D6C4BE4Q35566910-8C95632D-4D55-4C47-A0AF-38FEE2660100Q35579833-9152E404-56EF-4815-8852-987323167A92Q35731327-E3DA8A21-65F7-4BCD-8C06-0EAEF3A4D585Q36240086-706C46A2-2E44-45C4-8286-DF84177204DDQ36397384-CD2DCE8B-59B4-44D3-8510-4E564A84E5E6Q36727282-0EEF4D32-813D-43D1-B037-06182633B5E6Q36747913-2765229E-DD3F-47BA-9B94-0D65C13CF8CEQ36969977-22EFE7C7-DBCC-4491-85F7-F23F6BEE298CQ37263541-8535560A-9418-4A9F-AE8F-8630F73AEA6EQ37404676-680419D7-4011-4353-9807-76D09BB7B7E3Q37409900-82EB40EC-4E8F-4EE0-9AA6-EE713F7B7594Q37422462-4F500D58-99E4-4548-9C2C-8BC4A3452800Q37452008-A5395474-3ABD-40AD-B360-12D9B2070CA0Q37547275-ACA933EC-EE61-48B3-AAC8-7D7BAED889B4Q39174700-A7D5BC2B-E649-48EB-BB38-CC1588E554F1Q39539955-70405246-63C0-40BE-BA93-847F52231AF8Q39657878-7963C2E2-8AD9-4D62-B388-C718B5B856FDQ39683291-64A8DC42-3169-435F-ADAE-675C943B4232Q39699409-EFE4E8D3-476F-4C8C-B09C-9742BD4DC34DQ39796529-AD8976A3-7AD7-4D66-BF02-17A2B6C71DADQ40291316-2D706A61-DC6B-4A3F-8BF2-8EE53E0BC4F2Q40404514-26D07FBB-BCDB-45AB-83DA-6112442DEC59Q40721745-24E23570-F8FD-4719-BC18-61BBAA90263EQ41862836-4168E360-E9E9-48C1-8DBC-05C10E186035Q42117884-D676BF23-0C7C-43EE-B19D-3ACF4D675C96Q43077557-0E7502CF-60A1-4B36-BAE6-0ECF2970949C
P2860
Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@ast
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@en
type
label
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@ast
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@en
prefLabel
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@ast
Decreased processivity of huma ...... lamivudine-selected Met184Val.
@en
P2860
P1433
P1476
Decreased processivity of huma ...... lamivudine-selected Met184Val
@en
P2093
C S Crumpacker
P L Sharma
P2860
P304
P577
1999-10-01T00:00:00Z